Status:

TERMINATED

Topical Oxygen Therapy for Diabetic Wounds

Lead Sponsor:

Indiana University

Conditions:

Diabetic Foot Ulcers

Wound

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This is a pilot study which is intended to collect data to calculate an adequate sample size for a larger registered clinical trial. Eleven subjects were enrolled at The Ohio State University; we inte...

Detailed Description

There are a total of 5 study visits including the initial baseline visit were they will be randomized into one of the 2 groups (comparison or treatment). At the baseline visit the following will be co...

Eligibility Criteria

Inclusion

  • Age \>18 years
  • Able to give informed consent, willing and able to visit the hospital and CWC for regular treatment and follow-up visits.
  • Diabetic
  • -Chronic wound OR Foot Ulcer:
  • Ulcer present by history ≥ 4 weeks at time of enrollment
  • Compliant with standard wound care regimen
  • IF foot wound, Wagner grade 1 and 2, OR Wagner grade 3
  • Ulcer size: 0.6 cm2 to 20 cm2 and has not decreased in size by more than 30% in previous 2 weeks of the enrollment visit
  • Adequate circulatory status, as evidenced by any of the following:
  • Ankle Brachial Index (ABI) ≥0.7 - ≥ 1.20
  • If ABI non-compressible (ABI \>1.2), then toe brachial Index (TBI)\>0.5
  • SPP \> 30mmHg
  • TcOM \> 30mmHg
  • At least 4 weeks since revascularization procedure, if one has been performed
  • Able to complete Topical Oxygen Therapy 4 day/week for 16 weeks (must be able to remove existing wound dressing and apply TO2 Boot/treatment, and then re-dress wound)

Exclusion

  • Ulcer in area of radiation treatment.
  • Active malignancy at site of ulcer
  • Current treatment with wound VAC or weekly compression dressing
  • Untreated infection at site of ulcer (i.e. cellulitis or osteomyelitis)
  • If acute osteomyelitis has been diagnosed, patient may be enrolled only after the infection has been controlled. Including:
  • Debridement of infected bone if necessary
  • Patient has received at least 2 weeks of appropriate antibiotics
  • ABI \< 0.7 or \> 1.2

Key Trial Info

Start Date :

February 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 5 2021

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT02313428

Start Date

February 1 2020

End Date

August 5 2021

Last Update

April 25 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IU Health Methodist Hospital

Indianapolis, Indiana, United States, 46202